Van Nostrand D, Neutze J, Atkins F
J Nucl Med. 1986 Oct;27(10):1519-27.
Benua, Leeper, and others (BEL) have advocated the estimation of radiation exposure to the blood to select a more rational maximum safe dose of radioiodine (dosimetry) to treat metastatic functioning well-differentiated thyroid carcinoma. After adopting the BEL dosimetry approach, we reviewed the immediate (during hospitalization) and intermediate (from discharge up to 3 mo) side effects after our initial 15 therapies in ten patients. The doses ranged from 51 mCi (1,887 MBq) to 450 mCi (16.65 GBq). Immediate side effects were observed in 12/15 (80%), are described in detail, and were as follows: gastrointestinal 10/15, salivary 9/15, nonsalivary neck pain, swelling, etc. 2/15, pulmonary 0/15. Intermediate side effects were observed in 10/15 (67%), are described in detail, and were as follows: gastrointestinal 0/15, salivary 3/15, nonsalivary neck pain, swelling, etc. 3/15, nasal complaints 2/15, transient bone marrow suppression 9/10, pulmonary 0/15. No patient required blood transfusions or had complications secondary to reduced blood counts. All patient complaints resolved; however, several patients may have reduced baseline blood counts one year after therapy. No other long-term side effect has been noted but the mean follow-up has been only 15 mo. In our opinion, we have not observed any side effect to date which would contraindicate the continued use and evaluation of the BEL dosimetry approach.
贝努阿、利珀等人（BEL）主张通过估算血液辐射暴露量来选择更合理的放射性碘最大安全剂量（剂量测定法），以治疗转移性高分化甲状腺癌。采用BEL剂量测定法后，我们回顾了对10例患者进行的最初15次治疗后的即时（住院期间）和中期（出院后至3个月）副作用。剂量范围为51毫居里（1887兆贝克勒尔）至450毫居里（16650兆贝克勒尔）。15例中有12例（80%）出现即时副作用，详细情况如下：胃肠道反应15例中的10例，唾液腺反应15例中的9例，非唾液腺颈部疼痛、肿胀等15例中的2例，肺部反应15例中的0例。15例中有10例（67%）出现中期副作用，详细情况如下：胃肠道反应15例中的0例，唾液腺反应15例中的3例，非唾液腺颈部疼痛、肿胀等15例中的3例，鼻部不适15例中的2例，短暂性骨髓抑制10例中的9例，肺部反应15例中的0例。没有患者需要输血，也没有因血细胞计数减少而出现并发症。所有患者的不适症状均得到缓解；然而，有几名患者在治疗一年后可能基线血细胞计数有所降低。除平均随访时间仅15个月外，未发现其他长期副作用。我们认为，迄今为止，我们尚未观察到任何会妨碍继续使用和评估BEL剂量测定法的副作用。
